Therefore, a combinatorial therapy of nab-paclitaxel with an aldose-reductase inhibitor might delay the acquisition of nab-paclitaxel resistance in pancreatic cancer [57]. The gene discussed is AKR1B1; the disease is familial pancreatic carcinoma.